Avacopan for the Treatment of ANCA-Associated Vasculitis

Overview of attention for article published in New England Journal of Medicine, February 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 30 news outlets
blogs: 6 blogs
policy: 2 policy sources
twitter: 393 X users
patent: 6 patents
facebook: 4 Facebook pages

wikipedia: 4 Wikipedia pages
reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
bluesky: 5 Bluesky users
podcasts: 6 podcasts

Readers on

mendeley: 627 Mendeley

So far, Altmetric has seen 39 news stories from 30 outlets.

Controversial Drug Suspended Due to Trial Irregularities Medscape News UK15 minutes ago

Medscape, 03 Sep 2026

A review of the benefits and risks of avacopan (Avacopan Vifor) begun by the Medicines and Healthcare products Regulatory…

So leicht können Pharmafirmen Arzneimittelbehörden täuschen

Infosperber, 29 Jul 2026

Ein US-Hersteller erschlich die Zulassung eines Medikaments. Das kam aber erst Jahre später heraus.

New Data Lead to Decision to Revoke Autoimmune Disease Drug

Medscape, 26 Jun 2026

The European Medicines Agency (EMA) has recommended revoking the marketing authorization for Tavneos (avacopan, ChemoCentryx…

News story from Federal Register on Thursday 30 April 2026

Federal Register, 30 Apr 2026

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 35 additional news stories.